Abstract: This review summarizes data on the main approaches used for the search of biologically active compounds modulating the level and physiological activity of incretins. Currently two groups of drugs are used in clinical practice: they either replenish the deficit of incretins (glucagon-like peptide-1 receptor agonists) or inhibit the degradation processes (dipeptidyl peptidase 4 inhibitors). In addition, new groups of substances are actively searched. These include non-peptide agonists of glucagon-like peptide-1 receptors, agonists/antagonists of glucose-dependent insulinotropic peptide, the hybrid polypeptides based on glucagon-like peptide-1 and glucagon
Download PDF:
Reference: Spasov A.A., Chepljaeva N.I., Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2, Biomeditsinskaya khimiya, 2015, vol:
61(4), 488-496.
9. Frerker N., Raber K., Bode F., Skripuletz T., Nave H., Klemann C., Pabst R., Stephan M., Schade J., Brabant G. et al. (2009) Clin. Chem. Lab. Med., 47, 257-287. CrossRef Scholar google search
10. Sedo A., Duke-Cohan J. S., Balaziova E., Sedova L.R. (2005) Arthritis Res. Ther., 7(6), 253-269. CrossRef Scholar google search
25. Matthews J.E., Stewart M.W., De Boever E.H., Dobbins R.L., Hodge R.J., Walker S.E., Holland M.C., Bush M.A. (2008) J. Clin. Endocrinol. Metab., 93, 4810-4817. Scholar google search
26. Sebokova E., Bénardeau A., Sprecher U., Sewing S., Tobalina L., Migliorini C. (2010) Diabetes Obes. Metab., 12, 674-682. Scholar google search
27. Ratner R., Nauck M., Kapitza C., Asnaghi V., Boldrin M., Balena R. (2010) Diabet. Med., 27, 556-562. Scholar google search
28. Bergenstal R.M., Forti A., Chiasson J.L., Woloschak M., Boldrin M., Balena R. (2012) Diabetes Ther., 3(1), 13. Scholar google search
46. Eto T., Inoue S., Kadowaki T. (2012) Diabetes Obes. Metab., 14(11), 1040-1046. Scholar google search
47. Seewoodhary J., Bain S.C. (2011) Br. J. Gen. Pract., 61(582), 5-6. Scholar google search
48. Kshirsagar A.D., Aggarwal A.S., Harle U.N., Deshpande A.D. (2011) Diabetes Metab. Syndr., 5 (2), 105-112. Scholar google search
49. Claus T.H., Pan C.Q., Buxton J.M., Yang L., Reynolds J.C., Barucci N., Burns M., Ortiz A.A., Roczniak S., Livingston J.N., Clairmont K.B., Whelan J.P. (2007) J. Endocrinol., 192(2), 371-380. CrossRef Scholar google search
50. Claus T.H., Pan C.Q., Buxton J.M., Yang L., Reynolds J.C., Barucci N., Burns M., Ortiz A.A., Roczniak S., Livingston J.N., Clairmont K.B., Whelan J.P. (2006) J. Biol. Chem., 281(18), 12506-12515. Scholar google search
51. Tom I., Lee V., Dumas M., Madanat M., Ouyang J., Severs J., Andersen J., Buxton J.M., Whelan J.P., Pan C.Q. (2007) AAPS J., 9 (2), 227-234. Scholar google search
52. Mentlein R. (2009) Best Pract. Res. Clin. Endocrinol. Metab., 23(4), 443-452. Scholar google search
53. Irwin N., Flatt P.R. (2009) Best Pract. Res. Clin. Endocrinol. Metab., 23, 499-512. Scholar google search
54. Green B.D., Irwin N., Gault V.A. O'Harte F., Flatt P. (2005) Br. J. Diabetes Vasc. Dis., 5, 134-140. Scholar google search
55. Green B.D., Flatt P.R. (2007) Best Pract. Res. Clin. Endocrinol. Metab., 4(21), 497-516. Scholar google search
56. Tharakan G., Tan T., Bloom S. (2011) Trends Pharmacol. Sci., 32(1), 8-15. Scholar google search
57. Dhayal S., Morgan N.G. (2010) Drug News Perspect., 23(7), 418-424. Scholar google search
58. Overton H.A., Fyfe M.C.T., Reynet C. (2008) Br. J. Pharmacol., 153, S76-S81. Scholar google search
